Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery

Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery

Following its therapeutic effect in hematological metastasis, chimeric antigen receptor (CAR) T cell therapy has gained a great deal of attention during the last years. However, the effectiveness of this treatment has been hampered by a number of challenges, including significant toxicities, difficu...

Full description

Bibliographic Details
Main Authors: Theodora Katopodi, Savvas Petanidis, Doxakis Anestakis, Charalampos Charalampidis, Ioanna Chatziprodromidou, George Floros, Panagiotis Eskitzis, Paul Zarogoulidis, Charilaos Koulouris, Christina Sevva, Konstantinos Papadopoulos, Marios Dagher, Nikolaos Varsamis, Vasiliki Theodorou, Chrysi Maria Mystakidou, Nikolaos Iason Katsios, Konstantinos Farmakis, Christoforos Kosmidis
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Pharmaceutics
Subjects:
CAR T cell
reprogramming
immunoengineering
drug delivery
Online Access:https://www.mdpi.com/1999-4923/15/10/2458

Internet

https://www.mdpi.com/1999-4923/15/10/2458

Similar Items